Research Keyword: regulatory framework

Therapeutic and legal aspects of psilocybin in cancer-related depression

mycolabadmin

This paper examines how psilocybin, a naturally occurring psychoactive compound from mushrooms, could help cancer patients—especially those with head and neck cancer—who develop severe depression after surgery. Unlike traditional antidepressants that take weeks to work, psilocybin acts within hours, making it potentially ideal for patients needing rapid mental health support following disfiguring surgical procedures. However, while psilocybin is legal for medical or research use in several countries like Australia and Portugal, it remains restricted in Poland and many other places, creating legal barriers to its clinical implementation.

Read More »

Emerging Nonthermal Technologies for the Production of Postbiotics

mycolabadmin

Postbiotics are dead or inactivated beneficial microorganisms and their components that support human health without needing to survive in the gut. Traditional heat-killing methods damage these beneficial compounds. This comprehensive review explores six emerging technologies that can produce postbiotics while better preserving their health-promoting properties, making them more stable and effective for food and supplement applications.

Read More »

Nutrivigilance: the road less traveled

mycolabadmin

This paper discusses nutrivigilance, which is the monitoring of side effects from dietary supplements and health products. Unlike medicines, dietary supplements in the US don’t need approval before being sold to consumers. The paper explains what nutraceuticals are, how they’re classified, and the different ways the US and Europe try to keep track of harmful effects. The authors argue that better systems are needed, including more reporting from consumers and better communication between companies, regulators, and healthcare providers.

Read More »

Review of Psilocybin Use for Depression among Cancer Patients after Approval in Oregon

mycolabadmin

Psilocybin, the active compound in certain mushrooms, shows promise as a treatment for depression and anxiety in cancer patients, particularly those nearing end of life. Oregon legalized supervised psilocybin therapy in 2020, making it the first U.S. state to do so. While clinical research shows the treatment can rapidly reduce depression and improve quality of life, the actual rollout has faced challenges including regulatory hurdles, lack of professional standards, and unequal geographic access.

Read More »

Azole fungicides and Aspergillus resistance, five EU agency report highlights the problem for the first time using a One Health approach

mycolabadmin

A major European health agency report warns that widely-used fungicides sprayed on crops to prevent plant diseases may be creating resistant fungi that can infect humans and make medical treatments ineffective. The study found that about 10,000 tonnes of these azole fungicides are used in Europe annually, and their residues accumulate in the environment where they can cause harmful fungi to become resistant to the same medicines doctors use to treat patients. The report calls for urgent action to better monitor this problem and prevent resistance through smarter use and regulation of agricultural fungicides.

Read More »
Scroll to Top